Detail akcie Cervomed Rg online

Business Summary: CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, CervoMed Inc revenues decreased 47% to $4M. Net loss increased 97% to $18.9M. Revenues reflect Bio-Pharma segment decrease of 60% to $2.1M. Higher net loss reflects Bio-Pharma segment loss increase of 75% to $14.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.22 to -$2.10.